Hepatitis/MASH

The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.

Latest News

Liver with hepatitis/MASH -- Image credit: Rasi | stock.adobe.com
Efruxifermin Demonstrates Potential in Treating Patients With MASH-Related Scarring or Cirrhosis

February 5th 2025

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

Man experiencing pain in liver -- Image credit: eddows | stock.adobe.com
Model Estimates Prevalence of MASLD Will Increase From 33.7% in 2020 to 41.4% in 2050

January 31st 2025

Man with hepatitis MASH -- Image credit: Orawan | stock.adobe.com
Mitochondrial Dysfunction Present in Visceral Adipose Tissue in Patients With Obesity-Related MASH

January 29th 2025

Hepatitis E vaccine -- Image credit: anidimi | stock.adobe.com
Two-Dose Hepatitis E Virus Vaccination Regimen Demonstrates Efficacy, Study Finds

January 22nd 2025

Blood sample testing for hepatitis B virus -- Image credit: gamjai | stock.adobe.com
Xalnesiran Plus Immunomodulator Results in HBsAg Loss Among Patients With Chronic Hepatitis B

January 17th 2025

<1
...
3536373839